5561Tip sheets : promote the six protective behaviours to break the chain of COVID-19 transmissionTechnical Documents · December 21, 2020
5562Emergency use designation of COVID-19 candidate vaccines: ethical considerations for current and future COVID-19 placebo-controlled vaccine trials and trial unblinding: policy brief, 18 December 2020Technical Documents · December 18, 2020
5563SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide: web annex: country readiness checklist for SARS-CoV-2 antigen RDT implementationTechnical Documents · December 18, 2020
5564Public health surveillance for COVID-19: interim guidance, 16 December 2020Technical Documents · December 17, 2020
5568Measles and rubella elimination country profile: LuxembourgTechnical Documents · December 16, 2020
5569Measles and rubella elimination country profile: TajikistanTechnical Documents · December 16, 2020
5570Measles and rubella elimination country profile: the NetherlandsTechnical Documents · December 16, 2020
5572Профиль страны: элиминация кори и краснухи: Российская ФедерацияTechnical Documents · December 16, 2020
5573Measles and rubella elimination country profile: LithuaniaTechnical Documents · December 16, 2020
5574COVID-19 diagnostic testing in the context of international travel: scientific brief, 16 December 2020Technical Documents · December 16, 2020
5575Measles and rubella elimination country profile: Republic of MoldovaTechnical Documents · December 16, 2020
5577Measles and rubella elimination country profile: KyrgyzstanTechnical Documents · December 16, 2020
5579COVID-19 and the disruption of noncommunicable disease services: snapshot of survey results for the European RegionTechnical Documents · December 16, 2020
5580Measles and rubella elimination country profile: United Kingdom of Great Britain and Northern IrelandTechnical Documents · December 16, 2020